Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Body Protection Compound (BPC) Variants
Overview
BPC variants are synthetic peptide sequences related to a pentadecapeptide derived from human gastric juice, commonly designated BPC-157. These peptides are proposed to exhibit gastroprotective, angiogenic, and tissue repair properties through mechanisms that may involve nitric oxide pathways, growth factor modulation, and VEGF receptor interactions.
Mechanism of Action
The exact structure-activity relationships and receptor targets remain incompletely defined.
Research Summary & Key Findings
Preclinical rodent studies have reported accelerated healing of tendons, ligaments, and gastrointestinal lesions, along with protective effects in models of toxin-induced organ injury. Published research has primarily originated from a single research group, and independent replication is limited. No controlled clinical trials in humans have been published in peer-reviewed journals, and the compound lacks regulatory approval in any jurisdiction.
Clinical Status
Body Protection Compound (BPC) Variants is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Body Protection Compound Variants"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Body Protection Compound Variants"
Registered interventional and observational studies, including status and phase.
- PubChem: "Body Protection Compound Variants"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsNo lawful pathway today
Body Protection Compound (BPC) Variants is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.